GH Guardant Health, Inc.
XNAS
146.69
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- Nov 5 Reported earnings after the close: EPS −$0.29 vs −$0.75 est. (+61.3%), revenue $361M vs $351M est. (+2.9%) · −1.7% vs ±20.3% implied
- Nov 16 8-K: Material agreement, New debt obligation, Unregistered share sale, Other events
- Nov 17 Insiders sold $27.7K in 2 filings in 30 days
- Nov 18 3 planned insider sale notices (Form 144), $595.5K
- Oct 30 Short interest down 19% to 9.4M shares
- 52-Week Range
- $74.55 – $191.05
- YTD
- +44.18%
- IV Rank (30D)
- 31.31
- Straddle Price
- $20.05
- P/C Vol Ratio
- 1.42
- Market Cap
- $19.6B
- Open
- $148.50
- Day Range
- $145.40 – $155.97
- Volume
- 1,417,605
- Prev Close
- $145.14
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.43 |
| Cost of Equity (CAPM) | 12.99% (VRP-adj) |
| WACC | 11.93% |
| Volatility Risk Premium | +15.4pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +28.3% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | 175.8% |
| Book / Price | -1.4% |
| Gross Margin (TTM) | 65.2% |
| FCF Margin (TTM) | -18.2% |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $167.94 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $163.90 |
| Bollinger Width / SMA20 | 30.2% (drives anchor stability) |
| Net Debt | $0.5B |
| Market Cap | $19B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.3× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 28.9× · 4 peers |
| Peer P/B | n/a | 0% | median 15.3× · 8 peers |
| Peer P/S | $152.43 | 23% | median 14.6× · 8 peers |
| Market Anchor (SMA50) | $167.94 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $142.06 | 77% | 25 strikes · skew -0.13 |
- Industry (SIC)
- SERVICES-MEDICAL LABORATORIES (8071) · industry map
- Exchange
- XNAS
- Market Cap
- $19.6B
- Employees
- 2,506
- List Date
- 2018-10-04
- CIK
- 0001576280
- Last Earnings
- Nov 5 after close · −1.7% vs ±20.3% expected
- Next Earnings
- ~Feb 18, 2027 (estimated)
- Headquarters
- Palo Alto, CA
- Homepage
- https://www.guardanthealth.com
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 22.40% | -30.79% | 16.41% | -17.28% | 47.88% | 12.09% | 8.45% |
| Feb | -5.30% | -9.17% | -3.50% | -13.36% | -10.55% | -18.28% | -10.03% |
| Mar | 0.34% | -0.14% | -20.16% | 8.75% | 4.57% | 0.15% | -1.08% |
| Apr | 1.27% | -15.53% | -6.23% | -11.11% | 11.21% | -4.47% | -4.14% |
| May | -18.77% | -34.13% | 30.25% | 48.41% | -16.88% | 48.05% | 9.49% |
| Jun | 4.26% | 4.37% | 14.05% | 5.36% | 23.61% | 16.18% | 11.30% |
| Jul | -13.44% | 14.91% | 10.41% | 24.31% | -19.19% | -5.07% | 1.99% |
| Aug | 13.07% | 3.47% | 2.86% | -23.32% | 62.77% | 0.12% | 9.83% |
| Sep | -4.94% | 9.70% | -15.34% | -6.63% | -6.06% | 8.48% | -2.46% |
| Oct | 8.63% | -9.72% | -11.31% | -1.08% | 48.48% | 2.32% | 6.22% |
| Nov | -12.71% | 5.55% | -3.97% | 54.83% | 9.60% | -14.99%* | 6.38% |
| Dec | 2.42% | -48.10% | 2.73% | -13.99% | -2.93% | -- | -11.97% |
| Total | -9.87% | -76.48% | 5.10% | 27.01% | 208.50% | 35.19% | 31.57% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Strong momentum signals from technical indicators
- Positive news sentiment surrounding the company's cancer diagnostics market presence
- Moderate volatility, following market trends
Primary Risks:
- Potential for a pullback or consolidation phase if stock price reaches resistance levels
- Regulatory changes or FDA approvals affecting competition and market dynamics
Investment Thesis: GH is a compelling investment opportunity due to its strong technical momentum, positive news sentiment, and moderate risk profile. The company's presence in the rapidly growing cancer diagnostics market presents significant growth potential.
Recent News Sentiment Impact: The recent news headlines have been predominantly positive, highlighting GH's advancements in cancer biomarkers, ovarian cancer diagnostics, and AI-powered imaging systems. This has contributed to the bullish sentiment and upward price movement.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- Lower support: $144.27 (Bollinger Band)
- Middle resistance: $159.66 (SMA 50)
- Upper resistance: $175.06 (Upper Bollinger Band)
Momentum Signals: RSI: 62.52 (neutral), MACD signal line crossover above 0.27 (bullish), and Bollinger Bands position: neutral.
Volume Analysis:
- Volume SMA 20: 2277297.89
- On-Balance Volume (OBV): 122003248.51
- Volume Rate of Change: -12.76%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting GH's advancements in cancer diagnostics and biomarkers.
Sentiment Assessment: Positive sentiment dominates, with 5 out of 6 headlines having a positive or neutral tone.
Catalyst Identification: Upcoming FDA approvals, regulatory changes, and product launches could continue to drive growth and momentum.
Market Narrative: The news sentiment aligns with the technical signals, supporting the bullish trend.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-24 | After-Close | 12.04% | 7.88% | 0.65x | Within |
| 2021-05-06 | After-Close | 10.85% | 0.57% | 0.05x | Within |
| 2021-08-05 | After-Close | 10.49% | 1.15% | 0.11x | Within |
| 2021-11-04 | After-Close | 10.92% | 4.02% | 0.37x | Within |
| 2022-02-23 | After-Close | 17.39% | 10.01% | 0.58x | Within |
| 2022-05-05 | After-Close | 19.03% | 22.48% | 1.18x | Exceeded |
| 2022-08-04 | After-Close | 13.84% | 3.58% | 0.26x | Within |
| 2022-11-03 | After-Close | 21.73% | 4.93% | 0.23x | Within |
| 2023-01-09 | After-Close | 7.02% | 4.86% | 0.69x | Within |
| 2023-02-23 | After-Close | 9.09% | 11.68% | 1.28x | Exceeded |
| 2023-05-09 | After-Close | 13.42% | 14.92% | 1.11x | Exceeded |
| 2023-08-03 | After-Close | 11.71% | 6.42% | 0.55x | Within |
| 2023-11-06 | After-Close | 13.52% | 5.41% | 0.40x | Within |
| 2024-01-08 | After-Close | 10.44% | 3.23% | 0.31x | Within |
| 2024-02-22 | After-Close | 17.51% | 12.80% | 0.73x | Within |
| 2024-05-09 | After-Close | 10.96% | 15.07% | 1.38x | Exceeded |
| 2024-08-07 | After-Close | 12.66% | 10.87% | 0.86x | Within |
| 2024-11-06 | After-Close | 21.25% | 13.05% | 0.61x | Within |
| 2025-01-13 | After-Close | 7.41% | 1.68% | 0.23x | Within |
| 2025-04-30 | After-Close | 15.03% | 3.47% | 0.23x | Within |
| 2025-07-30 | After-Close | 15.82% | 9.32% | 0.59x | Within |
| 2025-10-29 | After-Close | 14.94% | 27.87% | 1.87x | Exceeded |
| 2026-02-19 | After-Close | 11.28% | 3.08% | 0.27x | Within |
| 2026-05-07 | After-Close | 15.07% | 3.73% | 0.25x | Within |
| 2026-07-30 | After-Close | 14.70% | 6.33% | 0.43x | Within |
| 2026-11-05 | After-Close | 20.27% | 1.67% | 0.08x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GH Options Activity & IV Rank
GH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
GH Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much GH actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 3rd percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $250.9M | #93 of 3716 | +10.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $217.5M | #176 of 6285 | +86.8% | 13F | |
| Point72 Hedge fund Steve Cohen | $138.1M | #117 of 1945 | +32.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2.9M | #1242 of 4858 | -13.4% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $637K | #893 of 997 | -68.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GH Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $53.33M | 31.23% | 2026-09-30 |
| 2 | Susquehanna International Group, LLP Custodian | $33.65M | 19.70% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $18.38M | 10.76% | 2026-06-30 |
| 4 | Walleye Capital LLC Custodian | $12.93M | 7.57% | 2026-09-30 |
| 5 | PEAK6 LLC | $11.75M | 6.88% | 2026-09-30 |
| 6 | Millennium Management LLC Custodian | $9.41M | 5.51% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $9.04M | 5.29% | 2026-09-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $6.40M | 3.75% | 2026-09-30 |
| 9 | Point72 Asset Management, L.P. | $4.88M | 2.85% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $4.28M | 2.51% | 2026-09-30 |
| 11 | Jefferies Financial Group Inc. | $2.85M | 1.67% | 2026-09-30 |
| 12 | Squarepoint Ops LLC | $2.05M | 1.20% | 2026-09-30 |
| 13 | Two Sigma Investments, LP Custodian | $1.34M | 0.78% | 2026-06-30 |
| 14 | D. E. Shaw & Co., Inc. Custodian | $495.10K | 0.29% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $60.34M | 28.54% | 2026-06-30 |
| 2 | Parallax Volatility Advisers, L.P. | $28.51M | 13.48% | 2026-06-30 |
| 3 | Eagle Health Investments LP | $26.81M | 12.68% | 2026-09-30 |
| 4 | Jane Street Group, LLC Custodian | $22.79M | 10.78% | 2026-09-30 |
| 5 | Portman Square Capital LLP | $16.91M | 8.00% | 2026-09-30 |
| 6 | IMC-Chicago, LLC Custodian | $10.40M | 4.92% | 2026-09-30 |
| 7 | Walleye Capital LLC Custodian | $9.61M | 4.55% | 2026-09-30 |
| 8 | Citadel Advisors LLC Custodian | $7.55M | 3.57% | 2026-06-30 |
| 9 | Jefferies Financial Group Inc. | $6.87M | 3.25% | 2026-09-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $6.03M | 2.85% | 2026-09-30 |
| 11 | Citigroup Inc. Custodian | $4.49M | 2.13% | 2026-09-30 |
| 12 | Simplex Trading, LLC Custodian | $2.69M | 1.27% | 2026-09-30 |
| 13 | D. E. Shaw & Co., Inc. Custodian | $2.39M | 1.13% | 2026-06-30 |
| 14 | Two Sigma Investments, LP Custodian | $2.18M | 1.03% | 2026-06-30 |
| 15 | Squarepoint Ops LLC | $2.07M | 0.98% | 2026-09-30 |
| 16 | Point72 Asset Management, L.P. | $1.77M | 0.84% | 2026-06-30 |
| 17 | PEAK6 LLC | $17.84K | <0.01% | 2026-09-30 |
GH Insider Trading (Form 4)
Latest: 2026-11-18| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-18 | Medina Manuel Hidalgo | Director | Exer (M) | +232 | — | EDGAR | |
| 2026-11-17 | Alex M Azar II | Director | Sell (S) | −69 | $149.56 | -$10.3K | EDGAR |
| 2026-11-17 | Musa Tariq | Director | Mixed Sell −116 · Exer +250 |
+134 | $149.56 | -$17.3K | EDGAR |
| 2026-11-13 | Kevin R Sayer | Director | Grant (A) | +3,149 RSU | — | EDGAR | |
| 2026-11-13 | Alex M Azar II | Director | Exer (M) | +138 | — | EDGAR | |
| 2026-11-12 | Robert Parks | Chief Accounting Officer | Grant (A) | +18,893 RSU | — | EDGAR | |
| 2026-10-22 | Roberto Mignone | Director | Exer (M) | +264 | — | EDGAR | |
| 2026-10-19 | Medina Manuel Hidalgo | Director | Exer (M) | +232 | — | EDGAR | |
| 2026-10-19 | Musa Tariq | Director | Mixed Sell −116 · Exer +250 |
+134 | $165.88 | -$19.2K | EDGAR |
| 2026-10-15 | Alex M Azar II | Director | Sell (S) | −69 | $159.89 | -$11.0K | EDGAR |
| 2026-10-13 | Alex M Azar II | Director | Exer (M) | +137 | — | EDGAR | |
| 2026-10-02 | Chris Freeman | Chief Commercial Officer | Mixed Exer +7,416 · Tax −3,143 |
+4,273 | $174.75 | -$549.2K | EDGAR |
| 2026-10-02 | Terilyn J. Monroe | Chief People Officer | Mixed Tax −2,098 · Exer +4,019 |
+1,921 | $174.75 | -$366.6K | EDGAR |
| 2026-10-02 | Helmy Eltoukhy | Co-Chief Executive Officer | Mixed Exer +36,530 · Tax −18,515 |
+18,015 | $175.03 | -$3.24M | EDGAR |
| 2026-10-02 | Darya Chudova | Chief Technology Officer | Mixed Tax −4,320 · Exer +8,033 |
+3,713 | $174.75 | -$754.9K | EDGAR |
GH Insider Holdings
18 insiders · @ $146.89| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Helmy Eltoukhy | Co-Chief Executive Officer | 1,958,949 | $287.75M | -$452.27M | 48 | 2026-10-02 |
| 2 | AmirAli Talasaz | Co-Chief Executive Officer | 1,842,366 | $270.63M | -$432.57M | 64 | 2026-10-02 |
| 3 | Darya Chudova | Chief Technology Officer | 128,828 | $18.92M | -$4.36M | 41 | 2026-10-02 |
| 4 | Craig Eagle | Chief Medical Officer | 72,001 | $10.58M | $0 | 30 | 2026-04-02 |
| 5 | Chris Freeman | Chief Commercial Officer | 69,647 | $10.23M | -$16.92M | 35 | 2026-10-02 |
| 6 | Michael Brian Bell | Chief Financial Officer | 55,182 | $8.11M | -$8.81M | 38 | 2026-10-02 |
| 7 | Kumud Kalia | Chief Information Officer | 42,773 | $6.28M | -$6.97M | 57 | 2026-10-02 |
| 8 | John G. Saia | Chief Legal Officer | 42,348 | $6.22M | -$4.25M | 58 | 2026-10-02 |
| 9 | Vijaya Gadde | Director | 28,517 | $4.19M | $0 | 8 | 2026-06-22 |
| 10 | Terilyn J. Monroe | Chief People Officer | 24,900 | $3.66M | -$15.95M | 17 | 2026-10-02 |
GH Board & Officers
As of SEC filings through Nov 17, 2026Directors 11
- AmirAli Talasaz · since Oct 3, 2018
- Helmy Eltoukhy · since Oct 3, 2018
- Ian T Clark · since Oct 3, 2018
- Vijaya Gadde · since Jun 12, 2020
- Myrtle S Potter · since Oct 15, 2021
- Steve E. Krognes · since Jun 30, 2022
- Musa Tariq · since Feb 21, 2023
- Medina Manuel Hidalgo · since Jul 17, 2024
- Roberto Mignone · since Oct 21, 2024
- Alex M Azar II · since Sep 12, 2025
- Kevin R Sayer · since Nov 2, 2026
Officers 9
- Helmy Eltoukhy · Chief Executive Officer · since Oct 3, 2018
- AmirAli Talasaz · Co-Chief Executive Officer · listed since Aug 2021
- Michael Brian Bell · Chief Financial Officer · since Jan 5, 2021
- Chris Freeman · Chief Commercial Officer · since Jun 28, 2021
- Kumud Kalia · Chief Information Officer · since May 1, 2022
- John G. Saia · Chief Legal Officer · listed since Mar 2023
- Darya Chudova · Chief Technology Officer · since May 3, 2023
- Terilyn J. Monroe · Chief People Officer · since Jan 2, 2024
- Robert Parks · Chief Accounting Officer · since Nov 2, 2026
Changes in the last 10 years (120)
| Nov 2, 2026 | Robert Parks became Chief Accounting Officer |
| Nov 2, 2026 | Kevin R Sayer became a director |
| Jun 22, 2026 | Meghan V. Joyce reported in an SEC filing no longer being a director |
| Apr 27, 2026 | The company announced the departure of Craig Eagle as Chief Medical Officer in an SEC filing |
| Sep 12, 2025 | Alex M Azar II became a director |
| Oct 21, 2024 | Roberto Mignone became a director |
| Jul 17, 2024 | Medina Manuel Hidalgo became a director |
| Mar 4, 2024 | Amelia Merrill reported in an SEC filing no longer being SVP, People |
| Jan 26, 2024 | The company announced the departure of Samir Kaul from the board in an SEC filing |
| Jan 2, 2024 | Terilyn J. Monroe became Chief People Officer |
| Nov 2, 2023 | The company announced the departure of Ines Dahne-Steuber as Chief Operating Officer in an SEC filing |
| May 3, 2023 | Ines Dahne-Steuber became Chief Operating Officer |
| May 3, 2023 | Darya Chudova became Chief Technology Officer |
| Mar 3, 2023 | John G. Saia listed as Chief Legal Officer (previously Senior Vice President, General Counsel and Corporate Secretary.) in SEC filings |
| Feb 21, 2023 | Musa Tariq became a director |
| Jun 30, 2022 | Steve E. Krognes became a director |
| May 4, 2022 | The company announced the departure of Bahija Jallal from the board in an SEC filing |
| May 1, 2022 | Kumud Kalia became Chief Information Officer |
| May 1, 2022 | Amelia Merrill became SVP, People |
| Feb 22, 2022 | The company announced the departure of Stanley J Meresman from the board in an SEC filing |
| Oct 15, 2021 | Myrtle S Potter became a director |
| Aug 17, 2021 | AmirAli Talasaz listed as Co-Chief Executive Officer (previously Chairman, President and COO) in SEC filings |
| Aug 4, 2021 | Meghan V. Joyce became a director |
| Jun 28, 2021 | Chris Freeman became Chief Commercial Officer |
| May 4, 2021 | Craig Eagle became Chief Medical Officer |
| Jan 5, 2021 | Michael Brian Bell became Chief Financial Officer |
| Oct 13, 2020 | Softbank Vision Fund (aiv M1) L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 13, 2020 | Sb Investment Advisers (uk) Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 13, 2020 | SVF Enterprise (Cayman) Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 13, 2020 | SVF Endurance (Cayman) Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 13, 2020 | SVF Bluebird (Cayman) Ltd reported in an SEC filing no longer being a 10% owner |
| Jun 12, 2020 | Vijaya Gadde became a director |
| May 6, 2020 | John G. Saia became Senior Vice President, General Counsel and Corporate Secretary. |
| Jul 5, 2019 | SVF Enterprise (Cayman) Ltd became a 10% owner |
| Jul 5, 2019 | SVF Endurance (Cayman) Ltd became a 10% owner |
| Jul 5, 2019 | SVF Bluebird (Cayman) Ltd became a 10% owner |
| Apr 17, 2019 | Bahija Jallal became a director |
| Oct 11, 2018 | Vinod Khosla reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | VK Services, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Temasek Life Sciences Private Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Temasek Holdings (Private) Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | TLS Beta Pte. Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Softbank Group Corp reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | SoftBank Group Capital Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sequoia Capital Usv Xiv Holdco, Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sequoia Capital U.s. Venture Partners Fund Xiv, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sequoia Capital U.s. Venture Partners Fund Xiv (q), L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sequoia Capital U.s. Venture Fund Xiv, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sequoia Capital U.s. Venture 2010-Seed Fund, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sequoia Capital Scout Fund II, L.l.c. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sc US (ttgp), Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sc U.s. Venture Xiv Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sc U.s. Venture 2010 Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Sandscape, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Ravi Mhatre reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Peter Nieh reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Orbimed Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed Venture Partners X, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed Venture Partners Select, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed Ultimate General Partner X, Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed Ultimate General Partner Select, Ltd. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed General Partner X, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed General Partner Select, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Lightspeed Affiliates X, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Khosla Ventures IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Khosla Ventures IV (CF), L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Khosla Ventures Associates IV, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Jeremy Liew reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Fullerton Management Pte Ltd reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Christopher J Schaepe reported in an SEC filing no longer being a 10% owner |
| Oct 11, 2018 | Barry Eggers reported in an SEC filing no longer being a 10% owner |
| Oct 3, 2018 | Vinod Khosla became a 10% owner |
| Oct 3, 2018 | VK Services, LLC became a 10% owner |
| Oct 3, 2018 | Temasek Life Sciences Private Ltd became a 10% owner |
| Oct 3, 2018 | Temasek Holdings (Private) Ltd became a 10% owner |
| Oct 3, 2018 | TLS Beta Pte. Ltd. became a 10% owner |
| Oct 3, 2018 | Stanley J Meresman became a director |
| Oct 3, 2018 | Softbank Vision Fund (aiv M1) L.p. became a 10% owner |
| Oct 3, 2018 | Softbank Group Corp became a 10% owner |
| Oct 3, 2018 | SoftBank Group Capital Ltd became a 10% owner |
| Oct 3, 2018 | Sequoia Capital Usv Xiv Holdco, Ltd. became a 10% owner |
| Oct 3, 2018 | Sequoia Capital U.s. Venture Partners Fund Xiv, L.p. became a 10% owner |
| Oct 3, 2018 | Sequoia Capital U.s. Venture Partners Fund Xiv (q), L.p. became a 10% owner |
| Oct 3, 2018 | Sequoia Capital U.s. Venture Fund Xiv, L.p. became a 10% owner |
| Oct 3, 2018 | Sequoia Capital U.s. Venture 2010-Seed Fund, L.p. became a 10% owner |
| Oct 3, 2018 | Sequoia Capital Scout Fund II, L.l.c. became a 10% owner |
| Oct 3, 2018 | Sc US (ttgp), Ltd. became a 10% owner |
| Oct 3, 2018 | Sc U.s. Venture Xiv Management, L.p. became a 10% owner |
| Oct 3, 2018 | Sc U.s. Venture 2010 Management, L.p. became a 10% owner |
| Oct 3, 2018 | Sb Investment Advisers (uk) Ltd became a 10% owner |
| Oct 3, 2018 | Sandscape, LLC became a 10% owner |
| Oct 3, 2018 | Samir Kaul became a director |
| Oct 3, 2018 | Richard B. Lanman became Chief Medical Officer |
| Oct 3, 2018 | Ravi Mhatre became a 10% owner |
| Oct 3, 2018 | Peter Nieh became a 10% owner |
| Oct 3, 2018 | Orbimed Advisors LLC became a 10% owner |
| Oct 3, 2018 | Michael J Wiley became Chief Legal Officer |
| Oct 3, 2018 | Lightspeed Venture Partners X, L.P. became a 10% owner |
| Oct 3, 2018 | Lightspeed Venture Partners Select, L.P. became a 10% owner |
| Oct 3, 2018 | Lightspeed Ultimate General Partner X, Ltd. became a 10% owner |
| Oct 3, 2018 | Lightspeed Ultimate General Partner Select, Ltd. became a 10% owner |
| Oct 3, 2018 | Lightspeed General Partner X, L.P. became a 10% owner |
| Oct 3, 2018 | Lightspeed General Partner Select, L.P. became a 10% owner |
| Oct 3, 2018 | Lightspeed Affiliates X, L.P. became a 10% owner |
| Oct 3, 2018 | Leena Das-Young became Chief LUNAR Officer and GM |
| Oct 3, 2018 | Khosla Ventures IV, L.P. became a 10% owner |
| Oct 3, 2018 | Khosla Ventures IV (CF), L.P. became a 10% owner |
| Oct 3, 2018 | Khosla Ventures Associates IV, LLC became a 10% owner |
| Oct 3, 2018 | Jeremy Liew became a 10% owner |
| Oct 3, 2018 | Ian T Clark became a director |
| Oct 3, 2018 | Helmy Eltoukhy became a director |
| Oct 3, 2018 | Helmy Eltoukhy became Chief Executive Officer |
| Oct 3, 2018 | Fullerton Management Pte Ltd became a 10% owner |
| Oct 3, 2018 | Dipchand Nishar became a director |
| Oct 3, 2018 | Derek A Bertocci became Chief Financial Officer |
| Oct 3, 2018 | Christopher J Schaepe became a 10% owner |
| Oct 3, 2018 | Barry Eggers became a 10% owner |
| Oct 3, 2018 | AmirAli Talasaz became a director |
| Oct 3, 2018 | AmirAli Talasaz became Chairman, President and COO |
| Oct 3, 2018 | Aaref Hilaly became a director |
- Prev
- 1
- …
Not reported recently (6)
- Derek A Bertocci · Last reported as Chief Financial Officer in an SEC filing dated Sep 3, 2020
- Dipchand Nishar · Last reported as a director in an SEC filing dated May 20, 2020
- Michael J Wiley · Last reported as Chief Legal Officer in an SEC filing dated Apr 30, 2020
- Richard B. Lanman · Last reported as Chief Medical Officer in an SEC filing dated Nov 5, 2019
- Aaref Hilaly · Last reported as a director in an SEC filing dated Sep 3, 2019
- Leena Das-Young · Last reported as Chief LUNAR Officer and GM in an SEC filing dated Oct 3, 2018
GH Proposed Insider Sales (Form 144)
Latest: 2026-11-18What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | Monroe Terilyn J. | Officer | 3,842 | $547.1K | 2026-11-18 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-11-16 | Azar Alex M II | Director | 207 | $31.0K | 2026-11-16 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-11-16 | Tariq Musa | Director | 116 | $17.3K | 2026-11-16 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-10-16 | Tariq Musa | Director | 116 | $19.2K | 2026-10-16 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-10-14 | Azar Alex M II | Director | 69 | $11.0K | 2026-10-14 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-09-16 | Tariq Musa | Director | 116 | $20.3K | 2026-09-16 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-09-16 | Azar Alex M II | Director | 826 | $144.6K | 2026-09-16 | Charles Schwab & Co., Inc. | 10b5-1 | EDGAR |
| 2026-09-16 | Krognes Steve E. | Director | 6,674 | $1.17M | 2026-09-16 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2026-09-15 | Chudova Darya | Officer | 7,738 | $1.38M | 2026-09-15 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2026-09-11 | Kalia Kumud | Officer | 4,000 | $632.2K | 2026-09-11 | Charles Schwab & Co., Inc. | — | EDGAR |
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-16 | Material agreement · New debt obligation · Unregistered share sale · Other events | EDGAR |
| 2026-11-05 | Earnings results | EDGAR |
| 2026-11-03 | Director or officer change | EDGAR |
| 2026-11-03 | Director or officer change | EDGAR |
| 2026-07-30 | Earnings results | EDGAR |
| 2026-06-18 | Shareholder vote results | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.03% | $571.5M | — | 2026-10-31 |
| 2 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.28% | $511.0M | — | 2026-10-31 |
| 3 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.67% | $286.0M | — | 2026-10-31 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.29% | $272.1M | — | 2026-10-31 |
| 5 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.44% | $100.2M | — | 2026-08-31 |
| 6 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.53% | $93.1M | $17.4B | 2026-11-16 |
| 7 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.14% | $79.6M | $57.0B | 2026-11-16 |
| 8 | VHT Vanguard Health Care ETF | Vanguard | 0.28% | $67.3M | — | 2026-10-31 |
| 9 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.05% | $61.5M | $113.5B | 2026-11-16 |
| 10 | CGGR Capital Group Growth ETF | Capitalgroup | 0.23% | $58.7M | $25.2B | 2026-11-16 |
| 11 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.39% | $58.3M | — | 2026-08-31 |
| 12 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.45% | $39.1M | $8.8B | 2026-11-16 |
| 13 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 2.32% | $37.5M | $1.6B | 2026-11-16 |
| 14 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.06% | $33.8M | — | 2026-10-31 |
| 15 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.44% | $29.9M | $6.7B | 2026-11-16 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.03% | $25.4M | $93.1B | 2026-11-16 |
| 17 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.93% | $25.1M | — | 2026-06-30 |
| 18 | PDP Invesco Dorsey Wright Momentum ETF | Nport | 1.71% | $24.6M | — | 2026-07-31 |
| 19 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 1.84% | $21.6M | $1.2B | 2026-11-16 |
| 20 | VT Vanguard Total World Stock ETF | Vanguard | 0.02% | $20.5M | — | 2026-10-31 |
| 21 | PSC Principal U.S. Small-Cap ETF | Nport | 0.87% | $20.3M | — | 2026-06-30 |
| 22 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.45% | $18.8M | $4.1B | 2026-11-16 |
| 23 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.19% | $17.1M | $9.0B | 2026-11-17 |
| 24 | IYH iShares U.S. Healthcare ETF | iShares (BlackRock) | 0.27% | $13.0M | $4.8B | 2026-11-16 |
| 25 | IWB iShares Russell 1000 ETF | iShares (BlackRock) | 0.03% | $12.8M | $46.6B | 2026-11-16 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $360.98M | $-124.36M | $-0.93 | $-23.71M |
| Q2 '26 | 2026-06-30 | $334.98M | $-120.14M | $-0.90 | $-57.78M |
| Q1 '26 | 2026-03-31 | $301.67M | $-112.08M | $-0.85 | $-65.62M |
| Q4 '25 | 2025-12-31 | $281.27M | $-128.49M | $-1.00 | $-26.37M |
| Q3 '25 | 2025-09-30 | $265.20M | $-92.72M | $-0.74 | $-35.41M |
| Q2 '25 | 2025-06-30 | $232.09M | $-99.90M | $-0.80 | $-60.28M |
| Q1 '25 | 2025-03-31 | $203.47M | $-95.16M | $-0.77 | $-62.69M |
| Q4 '24 | 2024-12-31 | $201.81M | $-111.01M | $-0.90 | $-64.51M |
| Q3 '24 | 2024-09-30 | $191.48M | $-107.75M | $-0.88 | $-51.06M |
| Q2 '24 | 2024-06-30 | $177.24M | $-102.63M | $-0.84 | $-94.00M |
| Q1 '24 | 2024-03-31 | $168.49M | $-114.98M | $-0.94 | $-30.28M |
| Q4 '23 | 2023-12-31 | $155.05M | $-187.04M | $-1.62 | $-78.84M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
GH vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.23T | 43.9 | +45.5% | +25.2% | 37 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $313.5B | 21.4 | +6.5% | −1.0% | 100 |
| GILD Gilead Sciences Inc | $209.6B | — | +6.5% | +37.2% | 64 |
| VRTX Vertex Pharmaceuticals Inc | $136.0B | 33.4 | +10.5% | +14.7% | 67 |
| MRNA Moderna, Inc. Common Stock | $79.6B | — | +13.1% | +547.8% | 37 |
| NTRA Natera, Inc. Common Stock | $42.0B | — | +37.4% | +27.3% | 60 |
| RVMD Revolution Medicines, Inc. Common Stock | $34.6B | — | — | +102.1% | 68 |
| GH Guardant Health, Inc. Common Stock | $19.6B | — | +41.7% | +44.4% | 31 |
| TWST Twist Bioscience Corporation Common Stoc | $7.9B | — | +22.0% | +247.3% | 51 |
| Peer median | $107.8B | 33.4 | +13.1% | +32.2% | 62 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.